MedCity News

OCTOBER 20, 2024

Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. During the recent MedCity News INVEST Digital Health conference, a panel discussed these applications and more. The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News.

Pharma 82

Pharma Leads Pharmaceutical Biopharma 82

pharmaphorum

OCTOBER 20, 2024

At its second attempt, Astellas won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for claudin 18.

FDA 64

FDA 64

MedCity News

OCTOBER 20, 2024

Research shows that medical residents of all specialties are avoiding states that ban abortion. This was discussed during a panel discussion at Engage at HLTH on Sunday in Las Vegas. The post How the Dobbs Decision Impacts Medical Practice Beyond Just OBGYNs appeared first on MedCity News.

Medical 66

Medical 66

PharmaTech

OCTOBER 20, 2024

Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed recent advancements and current challenges in the development of large RNA therapeutics.

52

52

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

OCTOBER 20, 2024

On the surface, it sounds positively delightful – who wouldn’t want to help dear grandma avoid the nursing home? But as is often the case with these sweeping government proposals, the devil is in the details. The post Why Harris’ Medicare at Home Plan is Good but Flawed appeared first on MedCity News.

Government 66

Government Patients Healthcare Healthcare 66

Pharmaceutical Technology

OCTOBER 20, 2024

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

52

52

Pharmacy Times

OCTOBER 20, 2024

In a study, RK-33 demonstrated positive effects against the protein DDX3, which is key in the growth of cancer cells and spreading of disease.

29

29

MedCity News

OCTOBER 20, 2024

Kaiser Permanente is showing no signs of slowing down when it comes to its Risant Health experiment. The organization is currently on the prowl for more acquisition targets, Kaiser CEO Greg Adams said at HLTH. The post Why Greg Adams Believes Risant Health Will Be Successful In Its Mission to Scale VBC Across the Country appeared first on MedCity News.

60

60